Welcome to our dedicated page for BioAge Labs news (Ticker: BIOA), a resource for investors and traders seeking the latest updates and insights on BioAge Labs stock.
BioAge Labs, Inc. develops clinical-stage biopharmaceutical candidates for cardiometabolic diseases by targeting the biology of human aging. Its news centers on BGE-102, a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases, including diabetic macular edema.
Recurring updates cover Phase 1 biomarker and tolerability data, indication development for inflammation-driven disease, and research into long-acting injectable and oral small-molecule APJ agonists for obesity. BioAge also reports financial results, public offerings, R&D presentations, and collaborations that use its human longevity data platform to identify metabolic-aging pathways.
BioAge (NASDAQ: BIOA) reported full-year 2025 results and Q4 updates on March 24, 2026. Key clinical highlights include positive interim Phase 1 data for oral NLRP3 inhibitor BGE-102 with an 86% median hsCRP reduction at 120 mg and planned Phase 2a initiation in 1H 2026. The company completed an upsized follow-on offering raising $132.3 million and held $285.1 million in cash and marketable securities as of December 31, 2025, estimating funding through 2029.
BioArctic (NASDAQ: B) reported new data presented at AD/PD 2026 on long-term, real-world IV lecanemab treatment persistence and additional company presentations. Real-world claims analysis showed 78.4% persistence at 18 months, 71.7% at 20 months and 67.3% at 24 months. BioArctic also presented data on lecanemab binding to soluble Aβ protofibrils and a poster on exidavnemab trial screening using alpha-synuclein SAA. The release notes investigational status and no guarantee of regulatory approval.
BioArctic (Nasdaq Stockholm: B) issued 78,000 Class B shares in February 2026 under the 2019/2028 stock option program. As of February 27, 2026 the company had 88,719,485 shares: 74,319,489 listed Class B and 14,399,996 unlisted Class A. A shares carry ten votes; B shares carry one vote, giving a total of 218,319,449 votes.
Contact details for investor relations are provided for further inquiries.
BioAge Labs (NASDAQ: BIOA) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026. CEO Kristen Fortney will join a fireside chat on February 26 from 10:40 AM to 11:05 AM ET; management will hold one-on-one meetings.
Live webcast registration is available and replays will be archived on the company's investor website for 30 days.
BioArctic (NASDAQ Stockholm: B) will publish its fourth quarter report for October–December 2025 on 18 February 2026 at 08:00 a.m. CET. A presentation with CEO Gunilla Osswald and CFO Anders Martin-Löf will follow at 09:30 a.m. CET, including a Q&A, webcast and teleconference options.
Registration links, dial-in information, and archived webcast access are provided on the company's investor site. Contact details for investor relations are listed for follow-up.
BioArctic (NASDAQ: B) reports that Leqembi global sales were JPY 20.7 billion in Q4 2025, generating a royalty to BioArctic of SEK 127 million. This royalty rose ~31% versus Q4 2024; at constant exchange rates the SEK increase would be ~50%, reflecting currency effects.
Eisai will publish its Q3 FY2025 results on February 9, 2026 and BioArctic will publish its FY2025 report on February 18, 2026 at 08:00 CET.
BioAge (Nasdaq: BIOA) priced an upsized underwritten public offering of 5,897,435 shares at $19.50 per share, producing gross proceeds of approximately $115.0 million. The offering is expected to close on or about January 23, 2026, subject to customary closing conditions. BioAge granted underwriters a 30-day option to purchase up to 884,615 additional shares. All shares are being offered by BioAge; proceeds are intended to fund research, clinical and process development and manufacturing (including BGE-102 and NLRP3 and APJ programs), working capital, capex, reduction of indebtedness and general corporate purposes.
Goldman Sachs, Piper Sandler and Citigroup are joint book-running managers; the offering is made under a Form S-3 registration that became effective November 25, 2025.
BioAge (Nasdaq: BIOA) on January 20, 2026 announced a proposed underwritten public offering of up to $75.0 million of common stock, with a 30-day underwriter option to purchase up to an additional $11.25 million. All shares will be offered by the company and the offering is subject to market and other conditions with no assurance of completion or final terms. Goldman Sachs, Piper Sandler and Citigroup are joint book‑running managers. Net proceeds, together with existing cash and marketable securities, are intended to fund research, clinical and process development including BGE-102, NLRP3 and APJ programs, working capital, capex and reduction of indebtedness. The offering will be filed on Form S-3.
BioAge (Nasdaq: BIOA) is expanding development of oral NLRP3 inhibitor BGE-102 into ophthalmology, initiating a Phase 1b/2a proof-of-concept trial in diabetic macular edema (DME) in mid-2026 with results expected mid-2027. BGE-102 showed favorable tolerability in Phase 1 and robust reductions in inflammatory biomarkers (hsCRP, IL-6, IL-1β). Preclinical data report near-complete protection from retinal vascular leakage and up to 90% microvascular preservation. The DME POC will test intraocular IL-6 percent change and include BCVA and CST endpoints.
BioAge (Nasdaq: BIOA) reported interim Phase 1 MAD cohort results for BGE-102, an oral, brain-penetrant NLRP3 inhibitor for patients with obesity and elevated inflammation. In the 120 mg once-daily cohort (n=14), BGE-102 achieved a 86% median hsCRP reduction at Day 14 and 93% of participants reached hsCRP <2 mg/L; 71% reached ≤1 mg/L. BGE-102 also produced a 44% median IL-6 reduction, 30% fibrinogen reduction, and 93% IL-1β suppression in an ex vivo assay. Safety was favorable with no dose-limiting toxicities. Company plans full Phase 1 readout and Phase 2a initiation in 1H 2026.